Accelerate Diagnostics, Inc: Nasdaq/NYSE listing notice — AXDX receives Nasdaq delisting notice for MVLS below $35M; 180-day cure period

Accelerate Diagnostics, Inc

Market Value of Listed Securities was below $35M for 31 consecutive business days.
Company has until September 3, 2024 to regain compliance by closing at $35M+ for 10 days.
May also consider increasing stockholders' equity to at least $2.5M to comply.
Notice does not immediately delist stock; failure to cure may lead to delisting.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.96

Accelerate Diagnostics, Inc received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2), 5810(c)(3)(C)

Exact text from the filing

March 4, 2024, Accelerate Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 31 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasd

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-24-031068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.